Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8784878 | ELI LILLY AND CO | Transdermal delivery rate control using amorphous pharmaceutical compositions |
Jul, 2023
(5 months from now) | |
US8993520 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(3 years from now) | |
US9180194 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(3 years from now) | |
US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(4 years from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.
Dosage: SOLUTION, METERED;TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6938798 | ELI LILLY AND CO | Fluid or powdery product dispensing device |
Jan, 2022
(1 year, 30 days ago) | |
US10213487 | ELI LILLY AND CO | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(13 years from now) | |
US10894133 | ELI LILLY AND CO | Device for dispensing a fluid product |
Jan, 2038
(14 years from now) | |
US10765602 | ELI LILLY AND CO | Medication delivery systems and methods |
Sep, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(8 years from now) | |
US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(8 years from now) | |
US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: May, 2026
Market Authorisation Date: 13 May, 2022
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Jun, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(6 years from now) | |
US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(9 years from now) | |
US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(9 years from now) | |
US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Mar, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | May 10, 2025 |
New Chemical Entity Exclusivity (NCE) | May 31, 2023 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: May, 2022
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of rheumatoid arthritis; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo); Treatment of adult patients with severe alopecia areata
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Apr, 2025
(2 years from now) | |
US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(a month from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Dec, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 28, 2022 |
New Patient Population (NPP) | Oct 12, 2024 |
New Indication (I) | Oct 12, 2024 |
Drugs and Companies using ABEMACICLIB ingredient
NCE-1 date: September, 2021
Market Authorisation Date: 28 September, 2017
Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with fulvestrant for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; As monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hr-positive, her2-negative, node-positive, early breast cancer at high risk of recurrence and a ki-67 score >=20%; In combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endrocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, and men with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic